One 5% yielder I’d consider over GlaxoSmithKline plc

Are you considering alternative dividend picks amid an earnings plateau at GlaxoSmithKline plc (LON:GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) faces a number of challenges in 2018.

With the drug maker unlikely to emerge from its earnings plateau for some time, amid growing competitive pressures in its HIV and respiratory businesses, there’s growing concern about the sustainability of its dividends.

Dividend frozen at 80p

GSK has frozen its annual dividend per share at 80p since 2015, but still it has struggled to generate enough profits and free cashflow to afford its current level of shareholder payouts. Net debt has climbed from £10.7bn at the end of 2015 to £14.2bn by the end of September 2017.

And although free cashflow has improved significantly in recent months, thanks to a positive currency benefit and the launch of new products, the company’s financial flexibility could come under pressure as it ponders the acquisition of Pfizer’s consumer health unit.

Little earnings movement

The earnings plateau is expected to continue for some time ahead, as the impact of new product launches is expected to be offset by the legacy effects of patent losses on key products like respiratory drug Advair. Although City analysts expect underlying earnings to have grown by 8% this year, they expect a 3% reversal this year. And for 2019, they think there will be a rebound in its bottom line of just 4%.

Although valuations aren’t pricey, with the shares trading at just 12.2 times expected earnings this year, the risk of a dividend cut continues to overhang its shares. As such, GSK’s current 6.1% dividend doesn’t tempt me right now.

A better pick

Instead, I reckon automotive, cycling and leisure retailer Halfords (LSE: HFD) represents a better dividend pick. In my view, the company has better fundamentals which give it a positive earnings outlook — an important criterion for dividend growth.

Halfords reported a 3.2% increase in sales over the 15 weeks to January 12, after strong trading in its cycling division. Like-for-like sales at its car maintenance division were also positive, with sales up 2.1% over the same period on improved car headlamp bulb and de-icer sales.

However, on the downside, Halfords cautioned that it expects the UK retail environment to “remain subdued” and warned that it would face higher costs because of the weaker pound. But I’m still more sanguine about its earnings prospects, due to the positive top-line picture, with growing like-for-like sales, and new store openings in the UK and in Europe.

Defensive appeal

In addition, unlike most retail stocks, Halfords is an intrinsically defensive stock. This is because car maintenance and repair, a non-cyclical business, makes up around 70% of revenues. After all, customers can’t avoid taking their cars for their annual MOT or conducting necessary repairs, due to legal requirements and the need to the keep their vehicles in good working order.

Halfords’ earnings multiples are similar to GSK’s, with shares in the retailer trading on 12.2 times expected earnings this year. And on top of this, the stock yields 5.1%

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the easyJet share price hit £10 in 2025?

easyJet has been trading well with rising earnings, which reflects in the elevated share price, but there may be more…

Read more »

Investing Articles

2 FTSE shares I won’t touch with a bargepole in 2025

The FTSE 100 and the FTSE 250 have some quality stocks. But there are others that Stephen Wright thinks he…

Read more »

Investing Articles

Could this be the FTSE 100’s best bargain for 2025?

The FTSE 100 is full of cheap stocks but there’s one in particular that our writer believes has the potential…

Read more »

Investing Articles

No Santa rally? As the UK stock market plunges 3%, I’m hunting for bargains

Global stock markets are in turmoil as Christmas approaches but our writer is keen to grab some bargains while prices…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

BP share price to surge by 70% in 12 months!? How realistic is that forecast?

Brand new analyst forecasts predict that the BP share price could rise considerably next year! Should investors consider buying this…

Read more »

Investing Articles

BT share price to double in 2025!? Here are the most up-to-date forecasts

The BT share price is up more than 40% over the last eight months with some analysts predicting it could…

Read more »

Investing Articles

Rolls-Royce share price to hit 850p!? Here are the latest expert projections

Analysts predict the Rolls-Royce share price could surge by another 50% in the next 12 months as free cash flow…

Read more »

Investing Articles

Will NatWest shares beat the FTSE 100 again in 2025? Here’s what the charts say

NatWest shares have left rivals Lloyds and Barclays in the dust in 2024. Stephen Wright looks at whether the stock's…

Read more »